LINC01134 and hepatocellular carcinoma: LINC01134 was found to recruit the transcription factor SP1 to the p62 promoter in hepatocellular carcinoma, which in turn activates the antioxidant pathway of p62 and regulates the resistance to oxaliplatin by affecting cell viability, apoptosis, and mitochondrial homeostasis [21].